Protagonist Therapeutics Revenue and Competitors

Newark,

Location

#9225

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Protagonist Therapeutics's estimated annual revenue is currently $28.7M per year.(i)
  • Protagonist Therapeutics's estimated revenue per employee is $193,750
  • Protagonist Therapeutics's total funding is $67M.

Employee Data

  • Protagonist Therapeutics has 148 Employees.(i)
  • Protagonist Therapeutics grew their employee count by 20% last year.

Protagonist Therapeutics's People

NameTitleEmail/Phone
1
EVP Program and Portfolio ManagementReveal Email/Phone
2
EVP, Chief Drug Discovery and Preclinical Development OfficerReveal Email/Phone
3
DirectorReveal Email/Phone
4
Project ManagerReveal Email/Phone
5
ScientistReveal Email/Phone
6
Administrative AssistantReveal Email/Phone
7
Executive AssistantReveal Email/Phone
8
President & CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Protagonist Therapeutics?

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Our platform enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity and selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications. We have successfully utilized this platform to discover PN-943 and PTG-200 which are oral, GI-restricted peptides for inflammatory bowel diseases (IBD), as well as PTG-300, an injectable peptide for rare blood disorders.

keywords:N/A

$67M

Total Funding

148

Number of Employees

$28.7M

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Protagonist Therapeutics News

2022-04-17 - PTGX stock hits 52-week low as Street reacts to ulcerative ...

The shares of Protagonist Therapeutics (NASDAQ:PTGX) have approached a 52-week low even as analysts defend the stock in reaction to the...

2022-04-17 - Protagonist Therapeutics shares slid after sharing Phase 2 data for its experimental ulcerative colitis treatment

Shares of Protagonist Therapeutics Inc. PTGX, -0.21% tumbled 30.8% in premarket trading on Tuesday the day after the company said a Phase 2...

2022-04-17 - Why Protagonist Therapeutics Shares Are Crashing Today - Benzinga

Protagonist Therapeutics Inc · 159 patients with moderate-to-severe active UC were randomized to either twice daily (BID) with 450 mg or 150 mg...

2021-08-10 - Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma

NEWARK, Calif., Aug. 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced it has resolved its Collaboration Agreement dispute with Zealand Pharma by reducing future development and sales milestone payments and royalties owed to ...

2021-07-28 - Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists

NEWARK, Calif., July 28, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced its entry into an amended collaboration agreement (the "Restated Agreement") with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Jo ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.6M148-7%N/A
#2
$41.3M150-11%N/A
#3
$44.6M1508%N/A
#4
$23.4M151-6%N/A
#5
$44.8M1519%N/A